SK Chemicals Co., Ltd. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'SK Chemicals Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the SK Chemicals Co., Ltd.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by SK Chemicals Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of SK Chemicals Co., Ltd. - The report provides overview of SK Chemicals Co., Ltd. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses SK Chemicals Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features SK Chemicals Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate SK Chemicals Co., Ltd.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for SK Chemicals Co., Ltd. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding SK Chemicals Co., Ltd.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 SK Chemicals Co., Ltd. Snapshot 6 SK Chemicals Co., Ltd. Overview 6 Key Information 6 Key Facts 6 SK Chemicals Co., Ltd. - Research and Development Overview 7 Key Therapeutic Areas 7 SK Chemicals Co., Ltd. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 SK Chemicals Co., Ltd. - Pipeline Products Glance 14 SK Chemicals Co., Ltd. - Late Stage Pipeline Products 14 Pre-Registration Products/Combination Treatment Modalities 14 Phase III Products/Combination Treatment Modalities 15 SK Chemicals Co., Ltd. - Clinical Stage Pipeline Products 16 Phase I Products/Combination Treatment Modalities 16 SK Chemicals Co., Ltd. - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Discovery Products/Combination Treatment Modalities 18 SK Chemicals Co., Ltd. - Drug Profiles 19 antihemophilic factor (recombinant) 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 NBP-603 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 NBP-606 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 NBP-607 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 THVD-201 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 NBP-608 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 NCE-403 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 SKI-2670 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 NBP-604 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 NBP-611 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 NCE-401 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 NCE-402 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 NCE-405 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 SID-111 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 SID-910 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 SID-920 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 SKI-2162 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 typhoid vaccine 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Vaccine 2 for Undisclosed Indication 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 pneumonia vaccine 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 SK Chemicals Co., Ltd. - Pipeline Analysis 40 SK Chemicals Co., Ltd. - Pipeline Products by Target 40 SK Chemicals Co., Ltd. - Pipeline Products by Route of Administration 41 SK Chemicals Co., Ltd. - Pipeline Products by Molecule Type 42 SK Chemicals Co., Ltd. - Pipeline Products by Mechanism of Action 43 SK Chemicals Co., Ltd. - Recent Pipeline Updates 44 SK Chemicals Co., Ltd. - Dormant Projects 47 SK Chemicals Co., Ltd. - Locations And Subsidiaries 48 Head Office 48 Other Locations & Subsidiaries 48 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables
SK Chemicals Co., Ltd., Key Information 6 SK Chemicals Co., Ltd., Key Facts 6 SK Chemicals Co., Ltd. - Pipeline by Indication, 2016 9 SK Chemicals Co., Ltd. - Pipeline by Stage of Development, 2016 10 SK Chemicals Co., Ltd. - Monotherapy Products in Pipeline, 2016 11 SK Chemicals Co., Ltd. - Partnered Products in Pipeline, 2016 12 SK Chemicals Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 13 SK Chemicals Co., Ltd. - Pre-Registration, 2016 14 SK Chemicals Co., Ltd. - Phase III, 2016 15 SK Chemicals Co., Ltd. - Phase I, 2016 16 SK Chemicals Co., Ltd. - Preclinical, 2016 17 SK Chemicals Co., Ltd. - Discovery, 2016 18 SK Chemicals Co., Ltd. - Pipeline by Target, 2016 40 SK Chemicals Co., Ltd. - Pipeline by Route of Administration, 2016 41 SK Chemicals Co., Ltd. - Pipeline by Molecule Type, 2016 42 SK Chemicals Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 43 SK Chemicals Co., Ltd. - Recent Pipeline Updates, 2016 44 SK Chemicals Co., Ltd. - Dormant Developmental Projects,2016 47 SK Chemicals Co., Ltd., Other Locations 48 SK Chemicals Co., Ltd., Subsidiaries 49
List of Figures
SK Chemicals Co., Ltd. - Pipeline by Top 10 Indication, 2016 8 SK Chemicals Co., Ltd. - Pipeline by Stage of Development, 2016 10 SK Chemicals Co., Ltd. - Monotherapy Products in Pipeline, 2016 11 SK Chemicals Co., Ltd. - Partnered Products in Pipeline, 2016 12 SK Chemicals Co., Ltd. - Pipeline by Top 10 Target, 2016 40 SK Chemicals Co., Ltd. - Pipeline by Route of Administration, 2016 41 SK Chemicals Co., Ltd. - Pipeline by Molecule Type, 2016 42 SK Chemicals Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016 43
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet oRead More...
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.